The prognostic value of neurohormonal and inflammatory biomarkers in addition to the TIMI risk score in patients with ST-elevation myocardial infarction.

Background: The Thrombolysis in Myocardial Infarction (TIMI) risk score estimates mortality for patients with ST-elevation myocardial infarction (STEMI). This study aimed to investigate whether biomarkers reflecting the neurohormonal response (pro-atrial natriuretic peptide (proANP), mid-regional pro-adrenomedullin (MR-proADM), and copeptin), inflammation (suppression of tumorigenicity 2 (ST2), C-reactive protein (CRP), and leukocytes), and troponin add prognostic value to the TIMI risk score.

Methods: This sub-study of the prospective PREDICT cohort included 1700 non-comatose and non-cardiogenic shock STEMI patients upon admission.

Effects of acute hydration changes on cardiovascular magnetic resonance native T1 and T2 mapping.

Changes in hydration status may affect myocardial native T1 and T2 values and influence the clinical interpretation. We aimed to assess the impact of acute preload augmentation on native T1 and T2. Cardiovascular magnetic resonance (CMR) native T1 and T2 mapping were performed twice on the same day in 20 healthy participants before and after an acute preload augmentation by a 2-liter intravenous infusion of isotonic sodium chloride (0.

Neurohormonal response is associated with mortality in women with STEMI.

Background: The prognosis after ST-elevation myocardial infarction (STEMI) continues to be worse in women. We hypothesize that sex-based differences in neurohormonal response may be a contributor to sex-specific differences in mortality risk.

Aims: To investigate whether the association between sex and mortality could in part be explained by levels of neurohormonal activation in patients with STEMI.

Interleukin-6 receptor antibodies (tocilizumab) in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (DOBERMANN-T): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial.

Background: Inflammation and neurohormonal activation play a significant role in the adverse outcome seen in acute myocardial infarction (AMI) and the development of cardiogenic shock (CS), which is associated with a mortality rate up to 50%. Treatment with anti-inflammatory drugs such as tocilizumab, an interleukin-6 receptor antagonist, has been shown to reduce troponin release and reduce the myocardial infarct size in AMI patients and it may therefore have cardioprotective properties.

Methods: This is a double-blind, placebo-controlled, single-center randomized clinical trial, including adult AMI patients without CS at hospital arrival, undergoing percutaneous coronary intervention (PCI) within 24 h from symptom onset, and at intermediate to high risk of developing CS (ORBI risk score ≥ 10).